- Home
- RSLS vs JAGX Comparison
RSLS vs JAGX Comparison
Compare RSLS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- JAGX
- Stock Information
- Founded
- RSLS 2002
- JAGX 2013
- Country
- RSLS United States
- JAGX United States
- Employees
- RSLS N/A
- JAGX N/A
- Industry
- RSLS Medical/Dental Instruments
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- JAGX Health Care
- Exchange
- RSLS Nasdaq
- JAGX Nasdaq
- Market Cap
- RSLS 4.5M
- JAGX 4.8M
- IPO Year
- RSLS 2007
- JAGX N/A
- Fundamental
- Price
- RSLS $2.56
- JAGX $2.70
- Analyst Decision
- RSLS Hold
- JAGX Strong Buy
- Analyst Count
- RSLS 1
- JAGX 1
- Target Price
- RSLS N/A
- JAGX $60.00
- AVG Volume (30 Days)
- RSLS 7.3M
- JAGX 84.1K
- Earning Date
- RSLS 08-13-2025
- JAGX 08-12-2025
- Dividend Yield
- RSLS N/A
- JAGX N/A
- EPS Growth
- RSLS N/A
- JAGX N/A
- EPS
- RSLS N/A
- JAGX N/A
- Revenue
- RSLS $7,175,000.00
- JAGX $11,552,000.00
- Revenue This Year
- RSLS $52.80
- JAGX $22.41
- Revenue Next Year
- RSLS N/A
- JAGX $30.00
- P/E Ratio
- RSLS N/A
- JAGX N/A
- Revenue Growth
- RSLS N/A
- JAGX 13.93
- 52 Week Low
- RSLS $2.23
- JAGX $2.61
- 52 Week High
- RSLS $414.99
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- RSLS 36.91
- JAGX 24.80
- Support Level
- RSLS $2.45
- JAGX $3.71
- Resistance Level
- RSLS $2.87
- JAGX $3.92
- Average True Range (ATR)
- RSLS 0.68
- JAGX 0.28
- MACD
- RSLS 0.14
- JAGX 0.02
- Stochastic Oscillator
- RSLS 5.45
- JAGX 2.37
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.